{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:24:59Z","timestamp":1707524699763},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,12]]},"DOI":"10.7759\/cureus.31411","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T15:28:42Z","timestamp":1668266922000},"source":"Crossref","is-referenced-by-count":0,"title":["Hyperlipidemia in the Setting of Primary Biliary Cholangitis: A Case Report and Review of Management Strategies"],"prefix":"10.7759","author":[{"given":"Ange","family":"Ahoussougbemey Mele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riaz","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Ogbuagu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Fombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(95)90413-1","article-title":"Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics","volume":"21","author":"Gylling H","year":"1995","unstructured":"Gylling H, F\u00e4rkkil\u00e4 M, Vuoristo M, et al.. Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. Hepatology. 1995, 21:89-95. 10.1016\/0270-9139(95)90413-1","journal-title":"Hepatology"},{"key":"ref2","article-title":"Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification","volume":"89","author":"Jahn CE","year":"1985","unstructured":"Jahn CE, Schaefer EJ, Taam LA, et al.. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 1985, 89:1266-78.","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo M","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, Podda M. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002, 51:265-9. 10.1136\/gut.51.2.265","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000029","article-title":"Metabolic syndrome associated with primary biliary cirrhosis","volume":"49","author":"Floreani A","year":"2015","unstructured":"Floreani A, Cazzagon N, Franceschet I, Canesso F, Salmaso L, Baldo V. Metabolic syndrome associated with primary biliary cirrhosis. J Clin Gastroenterol. 2015, 49:57-60. 10.1097\/MCG.0000000000000029","journal-title":"J Clin Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101124","article-title":"Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy","volume":"10","author":"Wah-Suarez MI","year":"2019","unstructured":"Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterol. 2019, 10:401-8. 10.1136\/flgastro-2018-101124","journal-title":"Frontline Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone NJ","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al.. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014, 129:S1-45. 10.1161\/01.cir.0000437738.63853.7a","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0988-9","article-title":"Statins in primary biliary cirrhosis: are they safe?","volume":"55","author":"Abu Rajab M","year":"2010","unstructured":"Abu Rajab M, Kaplan MM. Statins in primary biliary cirrhosis: are they safe?. Dig Dis Sci. 2010, 55:2086-8. 10.1007\/s10620-009-0988-9","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12191","article-title":"Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis","volume":"33","author":"Cash WJ","year":"2013","unstructured":"Cash WJ, O'Neill S, O'Donnell ME, et al.. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int. 2013, 33:1166-74. 10.1111\/liv.12191","journal-title":"Liver Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis","volume":"15","author":"Kim RG","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017, 15:1521-30.e8. 10.1016\/j.cgh.2017.04.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang XL","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L, et al.. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015, 13:123. 10.1186\/s12916-015-0358-8","journal-title":"BMC Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840170408","article-title":"Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis","volume":"17","author":"Poupon RE","year":"1993","unstructured":"Poupon RE, Ouguerram K, Chr\u00e9tien Y, Verneau C, Eschw\u00e8ge E, Magot T, Poupon R. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology. 1993, 17:577-82. 10.1002\/hep.1840170408","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/123736-hyperlipidemia-in-the-setting-of-primary-biliary-cholangitis-a-case-report-and-review-of-management-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:47Z","timestamp":1707507647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/123736-hyperlipidemia-in-the-setting-of-primary-biliary-cholangitis-a-case-report-and-review-of-management-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.31411","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,12]]}}}